ea0090rc7.1 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2023
Mangili Federica
, Muro Genesio Di
, Arlati Federico
, Barbieri Anna Maria
, E. G-Garcia Miguel
, Esposito Emanuela
, Treppiedi Donatella
, Catalano Rosa
, Marra Giusy
, Nozza E mma
, Locatelli Marco
, Lania Andrea
, Ferrante Emanuele
, Sala Elisa
, P. Castano Justo
, M. Luque Raul
, Arosio Maura
, Peverelli Erika
, Mantovani Giovanna
Dopamine receptor type 2 (DRD2) represents the main target for pharmacological therapy with dopamine agonists (DAs) in PRL-secreting neuroendocrine pituitary tumors (PRL-PitNET), even if about 10% of patients is resistant. A single paper recently described a somatic mutation in the gene encoding splicing factor 3B subunit 1 (SF3B1) in about 20% of patients with PRL-PitNET, that was associated with PRL hypersecretion, increased cell proliferation and invasion and reduced progre...